hepatocelluar carcinoma
Conditions
Interventions
single arm,test group:nimotuzumab,400mg,D1,8,15,28d/cycle
Sponsors
The Third Affiliated Hospital of Navy Military Medical University (Shanghai Eastern Hepatobiliary Surgery Hospital)
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) clinically or pathologically and cytologically diagnosed hepatocellular carcinoma; 2) confirmed radiographic progression after first-line treatment with lenvatinib with or without PD-1 monoclonal antibody; 3) high EGFR expression by immunohistochemistry or EGFR amplification by genetic testing in tumor tissue; 4) measurable lesions according to mRECIST criteria (see Appendix 1); 5) age from 18 to 75 years; 6) WHO/ECOG performance score (see Appendix 2) reached 0-2; 7) relatively adequate bone marrow hematopoietic reserve (neutrophil count > 1.0 x 10 ^ 9/L, platelet count > 50 x 10 ^ 9/L) 8) adequate liver reserve (bilirubin = 3 months 11) signed the informed consent
Exclusion criteria
Exclusion criteria: 1) after more than 2 lines of systemic therapy; 2) there are associated secondary malignant tumors or other tumors within 3 years before the start of the study, there are brain or meningeal metastases; 3) chronic diarrhea or colorectal inflammatory conditions, or affect systemic administration of untreated obstruction or subobstruction; 4) active infection or other serious infections that may hinder the patient from receiving planned treatment. For example, long-term uncontrolled destruction of biliary branch bacterial cholangitis; 5) history of uncontrolled drug abuse or mental disorders; 6) patients with concomitant diseases that may seriously endanger their own safety or may affect the completion of the study according to the investigator 's judgment; 7) participated in other clinical trials; 8) pregnant or lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| progress free suivival;overall survival;safety; | — |
Countries
China
Contacts
Public ContactYuan Zhengang
The Third Affiliated Hospital of Navy Military Medical University (Shanghai Eastern Hepatobiliary Surgery Hospital)
Outcome results
None listed